Abstract
1 In a double-blind study, 36 patients with essential hypertension were randomly allocated to treatment with either metoprolol, 100--300 mg/day, or pindolol, 5--15 mg/day for 6 months. Haemodynamic investigations were made on three separate occasions. Blood flow in the calves and in the forearm was determined by venous occlusion plethysmography after 6 weeks of placebo, after 6 weeks and again after 6 months of active therapy. 2 Both drugs reduced blood pressure significantly, by 17.1/11.8 mm Hg with metoprolol and 21.9/10.9 mm Hg with pindolol after 6 weeks (P less than 0.005). No further changes were seen after 6 months. 3 Heart rate after 6 weeks was significantly reduced by metoprolol (10.7 +/- 2.4 beats/min, P less than 0.001) but not by pindolol (4.4 +/- 2.3 beats/min, NS). After 6 months a significant reduction was seen also in the pindolol group (5.2 +/- 2.1 beats/min, P less than 0.05). 4 The vascular resistance in the calves at rest was reduced by pindolol (P less than 0.05), whereas resistance tended to increase with metoprolol. 5 Resting vascular resistance in the forearm after 6 months was significantly reduced in the metoprolol group (P less than 0.001) as well as in the pindolol group (P less than 0.02). The increase in forearm vascular resistance seen during leg exercise was not influenced by either drug. 6 Vascular resistance at maximal vasodilatation was unchanged in the calves, but a significant reduction (-17.4 +/- 5.7%, P less than 0.01) in the forearm vascular bed was seen after 6 months of pindolol. No change was observed with metoprolol. 7 It is concluded that pindolol reduces elevated blood pressure partly through peripheral vascular mechanism. Metoprolol, on the other hand, probably acts mainly via central cardiac mechanisms.
Full text
PDFSelected References
These references are in PubMed. This may not be the complete list of references from this article.
- Andersson O. Management of hypertension. Clinical and hemodynamic studies with special reference to patients refractory to treatment. Acta Med Scand Suppl. 1977;617:1–62. [PubMed] [Google Scholar]
- Atterhög J. H., Dunér H., Pernow B. Experience with pindolol, a betareceptor blocker, in the treatment of hypertension. Am J Med. 1976 May 31;60(6):872–876. doi: 10.1016/0002-9343(76)90907-4. [DOI] [PubMed] [Google Scholar]
- Atterhög J. H., Dunér H., Pernow B. Hemodynamic effect of long--term treatment with pindolol in essential hypertension with special reference to the resistance and capacitance vessels of the forearm. Acta Med Scand. 1977;202(6):517–521. doi: 10.1111/j.0954-6820.1977.tb16874.x. [DOI] [PubMed] [Google Scholar]
- Barrett A. M., Carter J. Comparative chronotropic activity of beta-adrenoceptive antagonists. Br J Pharmacol. 1970 Nov;40(3):373–381. doi: 10.1111/j.1476-5381.1970.tb10619.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- CONWAY J. A vascular abnormality in hypertension. A study of blood flow in the forearm. Circulation. 1963 Apr;27(4 Pt 1):520–529. doi: 10.1161/01.cir.27.4.520. [DOI] [PubMed] [Google Scholar]
- Frithz G. Initiation of once-daily pindolol treatment. Br Med J. 1978 Feb 4;1(6108):302–302. doi: 10.1136/bmj.1.6108.302-c. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gudbrandsson T. Malignant hypertension. A clinical follow-up study with special reference to renal and cardiovascular function and immunogenetic factors. Acta Med Scand Suppl. 1981;650:1–62. [PubMed] [Google Scholar]
- Hansson L., Zweifler A. J., Julius S., Hunyor S. N. Hemodynamic effects of acute and prolonged beta-adrenergic blockade in essential hypertension. Acta Med Scand. 1974 Jul-Aug;196(1-2):27–34. doi: 10.1111/j.0954-6820.1974.tb00962.x. [DOI] [PubMed] [Google Scholar]
- Imhof P. The significance of beta1-beta2-selectivity and intrinsic sympathomimetic activity in beta-blockers, with particular reference to antihypertensive treatment. Adv Clin Pharmacol. 1976;11:26–32. [PubMed] [Google Scholar]
- Johnsson G. Influence of metoprolol and propranolol on hemodynamic effects induced by adrenaline and physical work. Acta Pharmacol Toxicol (Copenh) 1975;36(Suppl 5):59–68. doi: 10.1111/j.1600-0773.1975.tb03322.x. [DOI] [PubMed] [Google Scholar]
- Lands A. M., Luduena F. P., Buzzo H. J. Differentiation of receptors responsive to isoproterenol. Life Sci. 1967 Nov 1;6(21):2241–2249. doi: 10.1016/0024-3205(67)90031-8. [DOI] [PubMed] [Google Scholar]
- Lund-Johansen P. Haemodynamics in essential hypertension. Clin Sci (Lond) 1980 Dec;59 (Suppl 6):343s–354s. doi: 10.1042/cs059343s. [DOI] [PubMed] [Google Scholar]
- Lund-Johansen P., Ohm O. J. Haemodynamic long-term effects of beta-receptor-blocking agents in hypertension: a comparison between alprenolol, atenolol, metoprolol and timolol. Clin Sci Mol Med Suppl. 1976 Dec;3:481S–483S. doi: 10.1042/cs051481s. [DOI] [PubMed] [Google Scholar]
- Lyngstam O., Rydén L. Metoprolol or atenolol for mild-to-moderate hypertension. Lancet. 1979 Sep 22;2(8143):634–634. doi: 10.1016/s0140-6736(79)91690-8. [DOI] [PubMed] [Google Scholar]
- Man in 't Veld A. J., Schalekamp M. A. Pindolol acts as beta-adrenoceptor agonist in orthostatic hypotension: therapeutic implications. Br Med J (Clin Res Ed) 1981 Mar 21;282(6268):929–931. doi: 10.1136/bmj.282.6268.929. [DOI] [PMC free article] [PubMed] [Google Scholar]
- PRICHARD B. N., GILLAM P. M. USE OF PROPRANOLOL (INDERAL) IN TREATMENT OF HYPERTENSION. Br Med J. 1964 Sep 19;2(5411):725–727. doi: 10.1136/bmj.2.5411.725. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Raftery E. B., Ward A. P. The indirect method of recording blood pressure. Cardiovasc Res. 1968 Apr;2(2):210–218. doi: 10.1093/cvr/2.2.210. [DOI] [PubMed] [Google Scholar]
- Sivertsson R., Andersson O., Hansson L. Blood pressure reduction and vascular adaptation. A study on long-term effects of treatment with mefruside or atenolol. Acta Med Scand. 1979;205(6):477–482. [PubMed] [Google Scholar]
- Sivertsson R. The hemodynamic importance of structural vascular changes in essential hypertension. Acta Physiol Scand Suppl. 1970;343:1–56. [PubMed] [Google Scholar]
- Stenberg J., Wasir H., Amery A., Sannerstedt R., Werkö L. Comparative hemodynamic studies in man of adrenergic bepta-1-receptors agents without (h 93/26 equal to metoprolol) or with (h 87/07) intrinsic sympathicomimetic activity. Acta Pharmacol Toxicol (Copenh) 1975;36(Suppl 5):76–84. doi: 10.1111/j.1600-0773.1975.tb03324.x. [DOI] [PubMed] [Google Scholar]
- Svendsen T. L., Carlsen J. E., Hartling O., McNair A., Trap-Jensen J. A comparison of the acute haemodynamic effects of propranolol and pindolol at rest and during supine exercise in man. Clin Sci (Lond) 1980 Dec;59 (Suppl 6):465s–468s. doi: 10.1042/cs059465s. [DOI] [PubMed] [Google Scholar]
- Svendsen T. L., Hartling O. J., Trap-Jensen J., McNair A., Bliddal J. Adrenergic beta receptor blockade: hemodynamic importance of intrinsic sympathomimetic activity at rest. Clin Pharmacol Ther. 1981 Jun;29(6):711–718. doi: 10.1038/clpt.1981.100. [DOI] [PubMed] [Google Scholar]
- Tarazi R. C., Dustan H. P. Beta adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations. Am J Cardiol. 1972 May;29(5):633–640. doi: 10.1016/0002-9149(72)90164-6. [DOI] [PubMed] [Google Scholar]
- Thulesius O., Gjöres J. E., Berlin E. Vasodilating properties of beta-adrenoceptor blockers with intrinsic sympathomimetic activity. Br J Clin Pharmacol. 1982;13(Suppl 2):229S–230S. doi: 10.1111/j.1365-2125.1982.tb01917.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- WHITNEY R. J. The measurement of volume changes in human limbs. J Physiol. 1953 Jul;121(1):1–27. doi: 10.1113/jphysiol.1953.sp004926. [DOI] [PMC free article] [PubMed] [Google Scholar]
- van Herwaarden C. L., Binkhorst R. A., Fennis J. F., van t'Laar A. Effects of adrenaline during treatment with propranolol and metoprolol. Br Med J. 1977 Apr 16;1(6067):1029–1029. doi: 10.1136/bmj.1.6067.1029. [DOI] [PMC free article] [PubMed] [Google Scholar]